A Practical Approach to Problematic Breast Lesions
January 16 - 18, 2018
Physicians Can Earn A Maximum Of 17 AMA PRA Category 1 Credits™
Physicians Can Earn A Maximum Of 12 SAM Credit Hours
Laura C. Collins, M.D.
Beth Israel Deaconess Medical Center / Harvard Medical School
Dr. Laura Collins is the Director of Anatomic Pathology at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Pathology at Harvard Medical School in Boston. She has previously served as the Program Director of both the Residency and Selective Pathology Fellowship Training Programs at BIDMC. Dr. Collins earned her medical degree from the Charing Cross and Westminster Medical School in London, UK. She completed a residency in Anatomic and Clinical Pathology and Cytology Fellowship at BIDMC. Dr. Collins' research, teaching and clinical activities are focused on diseases of the breast. She is a member of the USCAP Board of Directors and current President of the Arthur Purdy Stout Society.
Edi Brogi, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center / Weill Cornell Medical College
Dr. Brogi is a graduate of the School of Medicine and Surgery at the University of Florence, Italy, and obtained her Ph.D. from the Italian Ministry of Research, Rome, Italy. She completed her residency in anatomic pathology at the Massachusetts General Hospital, followed by surgical pathology and cytopathology fellowships at the same Institution. She joined the Pathology department at Memorial Sloan-Kettering Cancer Center (MSKCC) in July 2000, and has been practicing there since, with focus on the diagnosis of breast diseases. She is an Attending Pathologist, and the Director of the Breast Pathology Team at MSKCC. She is also Professor of Clinical Pathology and Laboratory Medicine at Weill Cornell Medical College. Dr. Brogi held the position of Officer, and is currently the President of the International Society of Breast Pathology. She was a member of the Education Committee of the United States and Canadian Academy of Pathology. Dr. Brogi lectures widely in the United States and abroad. She co-directed a breast pathology course jointly organized by MSKCC and Harvard Medical School, and directs the breast component of the MSKCC Surgical Pathology of Neoplastic Diseases teaching course. She serves as an ad hoc reviewer for numerous journals, and is an Associate Editor of Archives of Pathology and Laboratory Medicine. Dr. Brogi has published more than 150 articles, books, and book chapters related to breast pathology, and is Associate Editor of Rosen's Breast Pathology (4th ed.) and Rosen's Breast Pathology Diagnosis By Needle Core Biopsy (4th ed.) textbooks.
Stuart J. Schnitt, M.D.
Dana-Farber / Brigham and Women’s Cancer Center / Harvard Medical School
Dr. Schnitt is the Chief of Breast Oncologic Pathology for the Dana-Farber/Brigham and Women’s Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital Breast Oncology Program, co-leader of the Dana Farber Harvard Cancer Center Breast Program, Senior Pathologist at Brigham and Women’s Hospital, a Professor of Pathology at Harvard Medical School and an internationally recognized expert in breast pathology.
He did his internship and residency in Anatomic and Clinical Pathology at Beth Israel Hospital in Boston followed by a fellowship in surgical pathology, also at Beth Israel Hospital. He was a faculty member in the Beth Israel Hospital/Beth Israel Deaconess Medical Center Department of Pathology from 1984-2017, including 11 years as Director of Anatomic Pathology and subsequently Vice Chair for Anatomic Pathology. He has published over 340 original articles, review articles, editorials, commentaries, and book chapters, primarily in the area of breast diseases. He has authored a popular breast pathology textbook entitled “Biopsy Interpretation of the Breast”, now its third edition. The first two editions of this book were also published in Chinese. In addition, he is one of the editors of the 4th Edition of the “World Health Organization Classification of Tumours of the Breast”, published in 2012 and is serving as an editor of the upcoming 5th Edition of the “World Health Organization Classification of Tumours of the Breast”.
Dr. Schnitt is a Past President of the United States and Canadian Academy of Pathology (2010-2011). Other notable honors include the Arthur Purdy Stout Society of Surgical Pathologists Annual Prize (1999), the Albany Medical College Distinguished Alumnus Award (2014), the Lynn Sage Distinguished Lecturer (2014), the Maude Abbot Lecture at the United States and Canadian Academy of Pathology Annual Meeting (2016), and the United States and Canadian Academy of Pathology F.K. Mostofi Distinguished Service Award (2018). He is particularly proud to have been involved in the training of 37 breast pathology fellows since 1995. He has lectured extensively around the world. His research interests and contributions to our understanding of benign breast diseases and breast cancer have been broad, but have largely focused on risk factors for local recurrence in patients with invasive breast cancer and ductal carcinoma in situ treated with breast conserving therapy, benign breast disease and breast cancer risk, and stromal-epithelial interactions in breast tumor progression.
Hannah Y. Wen, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
Dr. Hannah Y. Wen is an assistant attending pathologist, and director of breast pathology fellowship at Memorial Sloan Kettering Cancer Center, with clinical practice focused exclusively on the diagnosis of breast lesions. She received her MD degree from Peking University Health Science Center and PhD in Cancer Biology from MD Anderson Cancer Center. She completed residency training in Anatomic and Clinical Pathology at New York University Langone Medical Center, and Surgical Pathology and Breast Pathology fellowships at Memorial Sloan Kettering Cancer Center. Dr. Wen has authored 60 peer-reviewed publications, 3 book chapters, and has lectured at various nationally and international conferences. Her current research is focused on the genetic alterations of triple negative breast carcinoma and immunotherapy for patients with triple negative breast cancer.